KPV is a tripeptide composed of lysine, proline, and valine (Lys-Pro-Val), corresponding to the C-terminal fragment of the hormone alpha-MSH. It is studied primarily for potential anti-inflammatory properties.

What does research suggest about KPV?

Preclinical laboratory and animal studies, including rodent models of colitis, suggest KPV may have anti-inflammatory activity. Direct human clinical evidence is very limited, so these findings should be considered preliminary.

Is KPV approved by the FDA or other regulators?

No. KPV is not an approved medicine in the US, EU, or other major jurisdictions. It is generally sold with research-chemical status and is not tested to pharmaceutical standards.

Human safety data on KPV are limited and its long-term profile is not well characterized. Research-market purity is unverified, which adds further uncertainty about what a given product actually contains.

What are the known side effects of KPV?

Because human studies are scarce, the side-effect profile of KPV is not well established. The long-term effects in humans remain unknown.

Why is KPV linked to gut inflammation?

Much of the preclinical research on KPV has focused on models of intestinal inflammation, such as experimental colitis, where it has been reported to reduce inflammatory markers. This remains animal-model evidence rather than confirmed human benefit.

How does KPV relate to alpha-MSH and to melanotan peptides?

KPV is the last three amino acids (lysine-proline-valine) at the tail end of alpha-MSH, a naturally occurring hormone. It is studied specifically because that small fragment appears to carry anti-inflammatory activity while lacking the pigment-darkening effects associated with the fuller alpha-MSH molecule and with the separate melanotan tanning peptides, which are a different topic entirely. Being a fragment does not mean it is a proven or approved therapy in humans.

Why is KPV often discussed for gut issues specifically?

Much of the preclinical interest comes from animal studies of colitis and intestinal inflammation, which is why online discussion frequently frames it around the gut. It is important to read this honestly: those are laboratory models, not human clinical outcomes. Promising results in a mouse colitis model do not establish that the compound is safe or effective for any condition in people, and no such conclusion should be drawn from the current evidence.

Is oral KPV meaningfully different from other forms discussed online?

Communities often distinguish oral, topical, and injected use, partly because KPV is a very small peptide and researchers have looked at how it is absorbed and transported. This is a real area of scientific curiosity, but it does not translate into usage guidance. There is no established, evidence-backed regimen for any route in humans, and the purity and content of research-market material are unverified.

Where can I buy KPV and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Inflammation

Buy KPV – Vendors, Prices, Testing and Evidence

Buy KPV

Also known as: Lysine-Proline-Valine

Evidence grade C — Early / Preclinical

Short answer

A short tripeptide fragment of alpha-MSH discussed in the context of inflammation. Human evidence is limited.

Where can you buy KPV?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

KPV is the C-terminal tripeptide of the alpha-MSH hormone, studied for anti-inflammatory properties.

What is not established?

Very limited human data.

Safety

Human safety data is limited; research-market purity is unverified.

Regulatory status

Not an approved medicine. Research chemical status.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Vendor comparison

Buy KPV: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	KPV research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

KPV research product

Code PEPTIDES10 −10% · discount code details

What is it?

KPV is the C-terminal tripeptide of the alpha-MSH hormone, studied for anti-inflammatory properties.

Research and evidence

KPV is a short tripeptide made up of the amino acids lysine, proline, and valine (Lys-Pro-Val), and it corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Because the parent hormone alpha-MSH has well-documented immunomodulatory roles, researchers have investigated whether this small three-amino-acid sequence can retain part of that anti-inflammatory signalling in a more compact, more stable form. On peptides.cx, KPV is catalogued under the Inflammation category with an evidence score of C, reflecting that most of what is known about it comes from laboratory and animal models rather than robust human clinical trials.

The scientific interest in KPV centers on its proposed ability to dampen inflammatory pathways. Preclinical studies, particularly in rodent models of experimental colitis, have reported reductions in inflammatory markers and tissue damage, which is why gut inflammation is one of the most common topics of discussion around this peptide. Some in-vitro and animal work has also explored skin and wound-related contexts. However, it is important to be precise about the state of the evidence: the anti-inflammatory effects described for KPV are largely preclinical, and direct, well-controlled human clinical data are very limited. Mechanistic claims about how KPV signals within cells remain proposed and under investigation rather than established.

From a regulatory and safety standpoint, KPV is not an approved medicine in the United States, the European Union, or other major jurisdictions. Material sold under this name typically carries research-chemical status, meaning it is not manufactured, tested, or labelled to pharmaceutical standards, and the purity of research-market supply is unverified. Human safety data are limited, and the long-term profile is not well characterized. This page is intended as an educational reference summarizing what published research suggests about KPV; it is not medical advice, and nothing here should be read as a recommendation to use the peptide or as a claim that it treats, cures, or prevents any condition.

Evidence grade: C

Very limited human data. Preclinical work suggests anti-inflammatory activity in models of colitis.

Human evidence

Very limited human data.

Animal and preclinical evidence

Preclinical work suggests anti-inflammatory activity in models of colitis.

Proposed mechanisms

Discussed anti-inflammatory signalling
Proposed effects on gut inflammation

Safety concerns and known side effects

Human safety data is limited; research-market purity is unverified.

Unknown long-term profile

Regulatory status

Not an approved medicine. Research chemical status.

KPV research timeline

1980s–1990s
Researchers characterizing the hormone alpha-MSH identify its C-terminal tripeptide, Lys-Pro-Val (KPV), as the fragment carrying much of the molecule's anti-inflammatory activity.
1990s
Preclinical studies report that KPV retains anti-inflammatory signalling in cell and animal models despite being far smaller than the parent hormone, prompting interest in it as a minimal active fragment.
2000s
Laboratory work extends to gut-inflammation models, with rodent colitis studies frequently cited as suggesting reduced inflammatory markers; this remains preclinical.
2010s
Investigations into how KPV enters cells and its possible interaction with intestinal transporters appear in the literature, alongside continued animal-model research; robust human trials do not follow.
early 2020s
KPV gains visibility in the online research-chemical and peptide-community space, discussed for gut and skin inflammation despite the absence of approval and very limited human data.
2020s (ongoing)
No regulatory approval as a medicine in the EU or US; KPV remains in unapproved research-chemical status with human safety and efficacy still not established in controlled trials.

Frequently asked questions about KPV

What is KPV?: KPV is a tripeptide composed of lysine, proline, and valine (Lys-Pro-Val), corresponding to the C-terminal fragment of the hormone alpha-MSH. It is studied primarily for potential anti-inflammatory properties.
What does research suggest about KPV?: Preclinical laboratory and animal studies, including rodent models of colitis, suggest KPV may have anti-inflammatory activity. Direct human clinical evidence is very limited, so these findings should be considered preliminary.
Is KPV approved by the FDA or other regulators?: No. KPV is not an approved medicine in the US, EU, or other major jurisdictions. It is generally sold with research-chemical status and is not tested to pharmaceutical standards.
Is KPV safe?: Human safety data on KPV are limited and its long-term profile is not well characterized. Research-market purity is unverified, which adds further uncertainty about what a given product actually contains.
What are the known side effects of KPV?: Because human studies are scarce, the side-effect profile of KPV is not well established. The long-term effects in humans remain unknown.
Why is KPV linked to gut inflammation?: Much of the preclinical research on KPV has focused on models of intestinal inflammation, such as experimental colitis, where it has been reported to reduce inflammatory markers. This remains animal-model evidence rather than confirmed human benefit.
How does KPV relate to alpha-MSH and to melanotan peptides?: KPV is the last three amino acids (lysine-proline-valine) at the tail end of alpha-MSH, a naturally occurring hormone. It is studied specifically because that small fragment appears to carry anti-inflammatory activity while lacking the pigment-darkening effects associated with the fuller alpha-MSH molecule and with the separate melanotan tanning peptides, which are a different topic entirely. Being a fragment does not mean it is a proven or approved therapy in humans.
Why is KPV often discussed for gut issues specifically?: Much of the preclinical interest comes from animal studies of colitis and intestinal inflammation, which is why online discussion frequently frames it around the gut. It is important to read this honestly: those are laboratory models, not human clinical outcomes. Promising results in a mouse colitis model do not establish that the compound is safe or effective for any condition in people, and no such conclusion should be drawn from the current evidence.
Is oral KPV meaningfully different from other forms discussed online?: Communities often distinguish oral, topical, and injected use, partly because KPV is a very small peptide and researchers have looked at how it is absorbed and transported. This is a real area of scientific curiosity, but it does not translate into usage guidance. There is no established, evidence-backed regimen for any route in humans, and the purity and content of research-market material are unverified.
Where can I buy KPV and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

Gut inflammationSkin

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10